# US 11,304,905 B2 · Solid composition for quick ingestion with facilitated swallowing, in the form of solid, non-agglomerated particles, comprising two different types of particles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,304,905 B2
- Document ID: US11304905B2
- Status: Granted
- Kind: B2
- Application number: 16/330,288
- Filed: 2017-09-15
- Published: 2019-07-04
- Granted: 2022-04-19
- Earliest claimed: 2016-09-15
- Assignees: Unither Pharmaceuticals
- Applicants: Unither Pharmaceuticals
- Inventors: Jean-Luc Pougnas
- Web page: https://patentgrep.com/patent/US11304905B2

## CPC

- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/009: {Sachets, pouches characterised by the material or function of the envelope (with gastric retention A61K9/0065; sachets which are not administered but function merely as a container are classified according to the content, e.g. sachets comprising powder for reconstitution of a drink A61K9/0095)}
- A61K 9/145: {with organic compounds}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/606: having amino groups
- A61K 36/05: Chlorophycota or chlorophyta (green algae), e.g. Chlorella
- A61K 36/28: Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K 36/324: Boswellia, e.g. frankincense
- A61K 36/81: Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K 36/9066: Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
- A61K 36/9068: Zingiber, e.g. garden ginger
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A solid composition with rapid ingestion and facilitated swallowing, in the form of non-agglomerated solid particles, said composition comprising the following two different types of particle: Pa particles, with very low solubility in saliva and comprising at least one active ingredient, and Ps particles, rapidly soluble in saliva, characterised by an apparent density equal to or greater than approximately 0.6 g.cm−3, advantageously equal to or greater than approximately 0.7 g.cm−3, and preferably between 0.7 and 1.5 g.cm−3 inclusive.

## Claims

### Claim 1

A solid composition for administration to a human or animal individual comprising:
Pa particles comprising at least one active ingredient in sufficient quantity to administer a desired dose of active ingredient to said human or animal individual, wherein the Pa particles have very low solubility in saliva, and
Ps particles comprising at least one polyol with low glycaemic index and at least one natural index and at least one natural organic acid or a salt thereof, the weight ratio of the at least one natural organic acid or salt thereof/the at least one polyol with low glycaemic index being between 0.01 and 1 inclusive, the Ps particles having an apparent density equal to or greater than approximately 0.6 g.cm−3 and being rapidly soluble in saliva;
wherein said Ps particles are present in said composition in sufficient quantity to enable rapid ingestion and facilitated swallowing of said Pa particles in said human or animal individual; and
wherein the composition is in the form of non-agglomerated solid particles.

### Claim 2 (depends on 1)

The composition according to claim 1, comprising a homogeneous mixture of Pa and Ps particles.

### Claim 3 (depends on 1)

The composition according claims 1, wherein said at least one natural organic acid, or a salt thereof, is present in the Ps particles in a mass percentage not exceeding 50% of the total mass of the Ps particles.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the Ps particles have an average size less than or equal to approximately 500 μm.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the Ps particles are free from disintegrating agents.

### Claim 6 (depends on 1)

The composition according to claim 1, wherein the Pa particles are made up of or are coated with a hydrophobic material,
wherein the Pa particles are protected from moisture, have limited solubility in saliva, or both; or
wherein the release of at least one active ingredient contained therein in one or more parts of the digestive tract is modulated; or
wherein the Pa particles are protected from moisture, have limited solubility in saliva, or both and wherein the release of at least one active ingredient contained therein in one or more parts of the digestive tract is modulated.

### Claim 7 (depends on 1)

The composition according to claim 1, wherein the Pa particles have an average size of less than approximately 500 μm.

### Claim 8 (depends on 1)

The composition according to claim 1, wherein the average size of the Ps particles and the average size of the Pa particles are no more than 50% different from each other.

### Claim 9 (depends on 1)

The composition according to claim 1, wherein the composition is free from disintegrating agents.

### Claim 10 (depends on 1)

The composition according to claim 1, wherein the ratio between the mass of Pa particles and the mass of Ps particles is less than 10.

### Claim 11 (depends on 10)

The composition according to claim 10, wherein said ratio is less than or equal to 1.

### Claim 12 (depends on 1)

A medicine or a food supplement for human or animal use, comprising the composition according to claim 1.

### Claim 13 (depends on 1)

A sachet or stick comprising the composition according to claim 1.

### Claim 14

Particles comprising at least one polyol with low glyaecmic index and at least natural organic acid or salt thereof, the weight ratio of the at least one natural organic acid or a salt thereof/the at least one polyol with low glycaemic index being between 0.01 and 1 inclusive, the particles having an apparent density equal to or greater than approximately 0.6 g.cm−3 and being rapidly soluble in saliva.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the polyol is erythritol, and wherein the erythritol has a mass percentage of at least 50% of the total mass of the Ps particles.

### Claim 16 (depends on 1)

The composition of claim 1, wherein the Ps particles consist of at least one polyol with low glycaemic index.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the polyol is erythritol.

### Claim 18 (depends on 10)

The composition of claim 10 wherein the ratio between the mass of Pa particles and the mass of Ps particles is less than or equal to 2.5.